A fara kasuwancin kerechnology da aka tsara don kawar da sunadarai masu matsala a waje da sel ya tashe shari'ar miliyan 130 don fara shari'ar da ta gabata.
Farawa, Glycoera, za ta yi amfani da jerin kudaden BS don samar da bayanan asibiti na farko don shirinsa na kwarya, cuta ta rigakafi ta duba GE820. Yana yi niyyar kawo magani na rigakafi na biyu cikin gwajin ɗan adam.
Shugaban kungiyar Glycoeras Glycoras Gelen820 kamar yadda yake da irin mawuyacin hali da Shugaba a cikin Samfura. " Magungunan kwayoyi Igg4, wanda ke yalwar rigakafin abin da zai iya zama mai kariya ga rashin lafiyan, amma malfuncation kuma ya kai hari kan kyallen jikin mutum a ciki yanayi masu yawa na yau da kullun, a tsakanin su rikicewar fata pemphigus da yanayin koda na farko membranous nephropathy.
GE8220 RAYUWAR - Aiwatar da cutar da ke haifar da jiki cikin lalata wannan maganin Igg4. Bangare daya na kwayoyin da ke da ƙarfi ga antable da jan shi zuwa hanta. The other part then latches onto a receptor that absorbs IgG4 into cells, where it’s trashed by an internal protein-disposal system.
According to GlycoEra, preclinical testing has shown the approach can remove malfunctioning IgG4 antibodies with the type of precision not seen with other approaches. Ta yin haka, GE820 na iya guje wa manyan tasirin imprunsippressive na wasu magunguna na autoimmai. Yana iya sauƙaƙa sauƙaƙa "nauyi a kan tsarin kiwon lafiya," in ji Kaundi.
Marasa lafiya yawanci "an kula, suna samun sauki sosai, sannan su dawo cewa za su koma. "Gakarmu ba wai kawai yana ba da damar masu haƙuri su rayu da rayuwa mafi kyau ba, shi ma gabaɗaya yana ba da gudummawa don mafi kyawun tattalin arziƙin tattalin arziƙin."
Glycoera ya bayyana a fili wasu shirye-shirye guda uku a bayan GE820, amma ba a kayyade wanda cututtukan da suke yiwa ba. Kamfanin na iya gabatar da bukatar don fara gwaji don magani na biyu a cikin 2026, Dangane da gidan yanar gizon sa.
Novo Holdings Leed Glycoera's jerin gwan, wanda ya shafi kayan kwalliyar Roche da Bristol Myers Squibb, Sofinnova Abokan Fasaha da sauran kamfanonin.
"Abin da gaske ya kasance tare da Glycoera, cewa kuna da shi da amfani a cikin Autoimnes, Holdings abokin ciniki yana da ƙarfi sosai," in ji Nopo abokin tarayya Max Kisser. "Kamar yadda muke ganin sararin samaniya na autoimmin tana canzawa, ingantaccen zanen magunguna kamar Glycera za su zo kan gaba."
An nada Glycoeera bayan glycostalation, aikin da aka haɗe sarƙoƙin sukari zuwa sunadarai. Kamfanin yana hayin kai a wädenswil, Switzerland kuma yana da sawun ƙafa a cikin Newton, Massachusetts. An shafe shi daga cikin tarihin ilimin halittu na karya a ciki Janairu 2021, kuma aka tashe kusan dala miliyan 49 a cikin jerin kudade cewa Nuwamba.
Sabbin hanyoyin da kamfanin ya inganta shine karin tabbacin ci gaba da ci gaba da haka - Ana kiranta Dograders na Presoin, wanda ke ba da hanyar samun manyan hanyoyin gargajiya na gargajiya ba zai iya kaiwa ba. Bincike zuwa lalacewar furotin ya tafi tun daga Juya karni, samar da tsararrun kamfanoni ta amfani hanyoyi daban-daban zuwa lalata sunadarai masu cutarwa.
SAURARA:Reoposted daga biopharmadida. Idan akwai wasu damuwar haƙƙin mallaka, tuntuɓi ƙungiyar gidan yanar gizon don cirewa.
Lokacin Post: 2025 - 05 - 30:23:56
